Expert consensus on icotinib as adjuvant therapy for non-small cell lung cancer.
10.3760/cma.j.cn112152-20221028-00726
- Collective Name:China International Exchange and Promotive Association for Medical and Health Care;Guangdong Association of Thoracic Diseases
- Publication Type:Journal Article
- Keywords:
Epidermal growth factor receptor tyrosine kinase inhibitor;
Expert consensus;
Icotinib;
Lung neoplasms;
Postoperative adjuvant therapy
- MeSH:
Humans;
Carcinoma, Non-Small-Cell Lung;
Lung Neoplasms/surgery*;
Consensus;
Mutation;
ErbB Receptors/genetics*;
Crown Ethers/therapeutic use*;
Protein Kinase Inhibitors/therapeutic use*
- From:
Chinese Journal of Oncology
2023;45(1):31-38
- CountryChina
- Language:Chinese
-
Abstract:
Clinical studies have established the clinical application of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) adjuvant targeted therapy. Compared with chemotherapy, the high efficiency and low toxicity of targeted therapy increases the survival benefit of patients. Icotinib was the first EGFR-TKI with independent intellectual property rights in China and the third EGFR-TKI to be marketed in the world. In order to summarize the experience of icotinib and other EGFR-TKIs in the adjuvant treatment of non-small cell lung cancer and further standardize and guide the clinical application of icotinib, experts from the China International Exchange and Promotive Association for Medical and Health Care and the Guangdong Association of Thoracic Diseases have organized an expert consensus on the adjuvant treatment of non-small cell lung cancer with icotinib, which is expected to provide clinicians with evidence-based medical evidences for postoperative targeted drug using.
